Technical Data
N2700-09
Nitrotyrosine (nTyr)
Description:
The presence of nitrotyrosine has been detected in various inflammatory processes including atherosclerotic plaques. Nitrotyrosine is formed in tissues in the presence of the active metabolite NO. Various pathways including the formation of peroxynitrite lead to nitrotyrosine production. It is still unknown whether nitration is merely a footprint of oxidative stress, an important pathway of nitric oxide metabolism or a part of integral processes for maintaining cellular homeostasis.

Applications:
Suitable for use in ELISA, Western Blot, Immunoprecipitation and Immunohistochemistry. Other applications not tested.

Recommended Dilutions:
ELISA: 0.5-5ug/ml
Western Blot: 1-2ug/ml
Immunoprecipitation: ~5ug/IP reaction
Immunohistochemistry (Frozen, paraffin): 1-2ug/ml; Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0 for 10-20 minutes followed by cooling at RT for 20 minutes.
Optimal dilutions to be determined by the researcher.

Positive Control:
Western Blot: Peroxynitrite treated A431 cells lysates
Immunohistochemistry: Human pancreas tissue

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG13G210Affinity Purified
SizeStorageShippingSourceHost
100ug-20°CBlue IceMouse
Concentration:
~0.5mg/ml
Immunogen:
Nitrotyrosine
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 0.1% sodium azide.
Specificity:
Recognizes nitrotyrosine as both free amino acid and as present in nitrated proteins. Reactivity of this antibody with nitrated proteins is independent of the protein species of origin.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
US Biological application reference: 1. Idris-Khodja , N. and Schini-Kerth, V. (2012) Naunyn-Schmiedeberg’s Arch. Pharmacology DOI: 10.1007/s00210-012-0749-8. 2. Murphy, B. M. et al., (2009) Anal Chim Acta. 640:1-6. 1. Sampson, J.B., et al., Methods Enzymol. 269: 210–218 (1996). 2. Ter Steege, J.C., et al., Free Radic. Biol. Med. 25(8): 953–963 (1998). 3. Beckman, J.S., et al., Biological Chemistry 375: 81–88 (1994). 4. Kooy, N.W., et al., Am. J. Respir. Crit. Care Med. 151: 1250–1254 (1995). 5. Beckman, J.S., et al., PNAS 84: 1620–1624 (1990). 6. Nakaki, T. & Fujii, T., Jpn. J. Pharmacol. 79(2): 125–129 (1999).